AstraZeneca Pharma shines on planning to launch Trastuzumab deruxtecan in January 2024
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Astrazeneca Pharma India is currently trading at Rs. 4688.55, up by 74.85 points or 1.62% from its previous closing of Rs. 4613.70 on the BSE.
The scrip opened at Rs. 4700.00 and has touched a high and low of Rs. 4884.45 and Rs. 4676.35 respectively. So far 502 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 5000.55 on 10-Nov-2023 and a 52 week low of Rs. 3102.00 on 20-Apr-2023.
Last one week high and low of the scrip stood at Rs. 4884.45 and Rs. 4602.25 respectively. The current market cap of the company is Rs. 11534.25 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 5.11% and 19.90% respectively.
AstraZeneca Pharma India is planning to launch Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder (Enhertu) in January 2024 in India. Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
